Payment overview · 2025
General Payments
$2,195.09
117 reported records · 24 companies
Healthcare provider profile · identity verified
Cherian John, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BURGETTSTOWN, PA · NPI 1891792099
Verified facts
What the public records show
CMS Open Payments records show Cherian John, MD received $2,195.09 in general payments during 2025 across 117 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Brilinta, Eliquis, Farxiga, Jardiance, Ozempic, Rexulti, Trelegy Ellipta, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 909 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 909 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $329.04 | 15.0% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $237.49 | 10.8% | 13 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $184.41 | 8.4% | 12 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $171.93 | 7.8% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.59 | 6.5% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $123.45 | 5.6% | 7 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $116.22 | 5.3% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.61 | 4.5% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $85.32 | 3.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.17 | 3.7% | 5 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $79.89 | 3.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $79.14 | 3.6% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $69.51 | 3.2% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $60.68 | 2.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $56.79 | 2.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $46.28 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.76 | 1.6% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $33.86 | 1.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.55 | 1.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.70 | 1.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.63 | 1.2% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $25.98 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.47 | 1.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.62 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,195.09 | 117 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $235.13 | 13 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $184.41 | 12 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $171.93 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $143.59 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $123.36 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $123.13 | 7 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $118.07 | 7 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $116.22 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.61 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $85.32 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.96 | 4 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $79.89 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $79.14 | 5 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $69.51 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.57 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $65.44 | 4 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $60.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.01 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $46.28 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.55 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| CONFIRM RX Normalized: confirm rx |
Device | Abbott Laboratories | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 58 | exact normalized | Medicare Part D |
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 114 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 909 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 93 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
114 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
909 | 136 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
58 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
155 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
909 | 136 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1440 | 306 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1135 | 184 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1121 | 188 |
| Potassium Chloride | Potassium Chloride | 992 | 170 |
| Pantoprazole Sodium | Pantoprazole Sodium | 950 | 171 |
| Eliquis | Apixaban | 909 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 904 | 196 |
| Losartan Potassium | Losartan Potassium | 767 | 152 |
| Furosemide | Furosemide | 721 | 157 |
| Clopidogrel | Clopidogrel Bisulfate | 715 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 662 | 183 |
| Omeprazole | Omeprazole | 590 | 93 |
| Duloxetine Hcl | Duloxetine Hcl | 575 | 73 |
| Metformin Hcl | Metformin Hcl | 569 | 97 |
| Famotidine | Famotidine | 563 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 552 | 82 |
| Memantine Hcl | Memantine Hcl | 526 | 45 |
| Carvedilol | Carvedilol | 516 | 139 |
| Sertraline Hcl | Sertraline Hcl | 475 | 52 |
| Lisinopril | Lisinopril | 426 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 336 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 45 |
| Prednisone | Prednisone | 287 | 77 |
| Donepezil Hcl | Donepezil Hcl | 276 | 25 |
| Allopurinol | Allopurinol | 266 | 45 |
| Buspirone Hcl | Buspirone Hcl | 257 | 32 |
| Xarelto | Rivaroxaban | 247 | 57 |
| Levetiracetam | Levetiracetam | 246 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 246 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 228 | 87 |
| Citalopram Hbr | Citalopram Hydrobromide | 225 | 35 |
| Glimepiride | Glimepiride | 218 | 35 |
| Trazodone Hcl | Trazodone Hcl | 217 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 213 | 33 |
| Spironolactone | Spironolactone | 211 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 201 | 18 |
| Propranolol Hcl | Propranolol Hcl | 200 | 34 |
| Amiodarone Hcl | Amiodarone Hcl | 197 | 50 |
| Mirtazapine | Mirtazapine | 193 | 24 |
| Ranolazine Er | Ranolazine | 191 | 38 |
| Warfarin Sodium | Warfarin Sodium | 185 | 40 |
| Januvia | Sitagliptin Phosphate | 181 | 19 |
| Glipizide | Glipizide | 179 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 177 | 56 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 176 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 175 | 44 |
| Montelukast Sodium | Montelukast Sodium | 172 | 39 |
| Baclofen | Baclofen | 169 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 41 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 159 | 20 |
| Entresto | Sacubitril/Valsartan | 155 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 155 | 16 |
| Gabapentin | Gabapentin | 154 | 11 |
| Atenolol | Atenolol | 136 | 35 |
| Jardiance | Empagliflozin | 131 | 29 |
| Aripiprazole | Aripiprazole | 118 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 118 | 23 |
| Propafenone Hcl | Propafenone Hcl | 115 | 40 |
| Brilinta | Ticagrelor | 114 | 12 |
| Divalproex Sodium | Divalproex Sodium | 107 | 12 |
| Midodrine Hcl | Midodrine Hcl | 105 | 31 |
| Meloxicam | Meloxicam | 101 | 25 |
| Topiramate | Topiramate | 96 | 15 |
| Farxiga | Dapagliflozin Propanediol | 93 | 20 |
| Primidone | Primidone | 89 | suppressed |
| Simvastatin | Simvastatin | 89 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | 17 |
| Sotalol | Sotalol Hcl | 88 | suppressed |
| Naproxen | Naproxen | 87 | 34 |
| Ozempic | Semaglutide | 87 | 25 |
| Clonidine Hcl | Clonidine Hcl | 82 | 20 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 81 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 78 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 77 | 17 |
| Sucralfate | Sucralfate | 75 | 26 |
| Lamotrigine | Lamotrigine | 71 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 70 | 61 |
| Meclizine Hcl | Meclizine Hcl | 70 | 26 |
| Bumetanide | Bumetanide | 67 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 24 |
| Rivastigmine | Rivastigmine Tartrate | 65 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 64 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 58 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 12 |
| Finasteride | Finasteride | 56 | 12 |
| Levofloxacin | Levofloxacin | 55 | 42 |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 45 |
| Alendronate Sodium | Alendronate Sodium | 53 | 11 |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Gemfibrozil | Gemfibrozil | 53 | suppressed |
| Risperidone | Risperidone | 52 | suppressed |
| Ezetimibe | Ezetimibe | 51 | 12 |
| Glipizide Er | Glipizide | 51 | suppressed |
| Nitroglycerin | Nitroglycerin | 51 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 39 |
| Metolazone | Metolazone | 47 | 18 |
| Cholestyramine | Cholestyramine (With Sugar) | 46 | 26 |
| Tramadol Hcl | Tramadol Hcl | 46 | suppressed |
| Azithromycin | Azithromycin | 44 | 39 |
| Divalproex Sodium Er | Divalproex Sodium | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 40 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 42 | 15 |
| Ibuprofen | Ibuprofen | 41 | 14 |
| Colchicine | Colchicine | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 26 |
| Valsartan | Valsartan | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 38 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 12 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Zonisamide | Zonisamide | 33 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 23 |
| Repaglinide | Repaglinide | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 23 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Mesalamine | Mesalamine | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Lorazepam | Lorazepam | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Repatha Pushtronex | Evolocumab | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Imiquimod | Imiquimod | 14 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Clonidine | Clonidine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Ambrisentan | Ambrisentan | 11 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,195.09 · 117 records | AstraZeneca Pharmaceuticals LP | AREXVY, Attruby, BRILINTA, CONFIRM RX, Cologuard Collection Kit, ELIQUIS, FARXIGA, FFRct, JARDIANCE, Kerecis GraftGuide, Kerecis SurgiClose, Kerendia, Korlym, LEQVIO, LUMRYZ, LifeVest, NURTEC ODT, OPSYNVI, Ohtuvayre, Ozempic, PAXLOVID, REPATHA, REXULTI, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UPTRAVI, VERQUVO, Wegovy, XIFAXAN, YUPELRI | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error